NASDAQ:ALECAlector Stock Price, Forecast & News

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALEC stock has increased by 31.4% and is now trading at $32.74. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alector.

Alector is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Alector.

Alector Inc (NASDAQ:ALEC) issued its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.10. The company had revenue of $7.17 million for the quarter, compared to analyst estimates of $10.60 million. Alector had a negative net margin of 556.70% and a negative return on equity of 48.29%. View Alector's earnings history.

7 Wall Street analysts have issued 1 year target prices for Alector's shares. Their forecasts range from $28.00 to $32.00. On average, they anticipate Alector's share price to reach $29.67 in the next twelve months. This suggests that the stock has a possible downside of 9.4%. View analysts' price targets for Alector.

News stories about ALEC stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alector earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAlector.

Some companies that are related to Alector include BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), argenx (ARGX), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Crispr Therapeutics (CRSP), bluebird bio (BLUE) and Halozyme Therapeutics (HALO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Cisco Systems (CSCO), Harpoon Therapeutics (HARP), Johnson & Johnson (JNJ), Kaleido Biosciences (KLDO) and AT&T (T).

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by a variety of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (10.54%), Federated Hermes Inc. (5.61%), BlackRock Inc. (5.32%), RA Capital Management L.P. (5.22%), State Street Corp (1.44%) and Geode Capital Management LLC (0.70%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul and Sabah Oney. View institutional ownership trends for Alector.

ALEC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Franklin Resources Inc., Pictet Asset Management Ltd., Russell Investments Group Ltd., Morgan Stanley, UBS Group AG, Voloridge Investment Management LLC, and Ensign Peak Advisors Inc. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, and Sabah Oney. View insider buying and selling activity for Alector.

ALEC stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Federated Hermes Inc., Bank of New York Mellon Corp, Geode Capital Management LLC, Invesco Ltd., Cannell Peter B & Co. Inc., and State Street Corp. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc. View insider buying and selling activity for Alector.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALEC stock can currently be purchased for approximately $32.74.

Alector has a market capitalization of $2.59 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

The official website for Alector is www.alector.com.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]